Tolvaptan
| File:Tolvaptan.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
N-(4-{[(5R)-7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl}-3-methylphenyl)-2-methylbenzamide | |
| Clinical data | |
| [[Regulation of therapeutic goods |Template:Engvar data]] | |
| Pregnancy category |
|
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Unknown (40% absorbed) |
| Protein binding | 99% |
| Metabolism | Hepatic (CYP3A4-mediated)[1] |
| Biological half-life | 12 hours (terminal) |
| Identifiers | |
| CAS Number | 150683-30-0 |
| ATC code | C03XA01 (WHO) [2] |
| PubChem | CID 443894 |
| Synonyms | N-{4-[(6R)-9-chloro-6-hydroxy-2-azabicyclo[5.4.0]undeca-8,10,12-triene-2-carbonyl]-3-methyl-phenyl}-2-methyl-benzamide |
| Chemical data | |
| Formula | C26H25ClN2O3 |
| Molar mass | 448.941 g/mol[[Script error: No such module "String".]] |
Tolvaptan (INN), also known as OPC-41061, is a selective, competitive arginine vasopressin receptor 2 antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan was approved by the U.S. Food and Drug Administration on May 19, 2009, and is sold by Otsuka Pharmaceutical Co. under the trade name Samsca.
Tolvaptan is also in fast-track clinical trials[3] for polycystic kidney disease. In a 2004 trial, tolvaptan, when administered with traditional diuretics, was noted to increase excretion of excess fluids and improve blood sodium levels in patients with heart failure without producing side effects such as hypotension (low blood pressure) or hypokalemia (decreased blood levels of potassium) and without having an adverse effect on kidney function.[4]
Kondo, K.; Ogawa, H.; Yamashita, H.; Miyamoto, H.; Tanaka, M.; Nakaya, K.; Kitano, K.; Yamamura, Y.; Nakamura, S.; Onogawa, T.; et al.; Bioor. Med. Chem. 1999, 7, 1743.
Notes
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />References
- Gheorghiade M, Niazi I, Ouyang J; et al. (2003). "Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial". Circulation. 107 (21): 2690–6. doi:10.1161/01.CIR.0000070422.41439.04. PMID 12742979.
| 45px | This hormonal preparation article is a stub. You can help ssf by expanding it. |
| 40px | This antihypertensive-related article is a stub. You can help ssf by expanding it. |
- ↑ Shoaf S, Elizari M, Wang Z; et al. (2005). "Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias". J Cardiovasc Pharmacol Ther. 10 (3): 165–71. doi:10.1177/107424840501000304. PMID 16211205.
- ↑ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Retrieved 2008-09-05.
- ↑ Otsuka Maryland Research Institute, Inc.
- ↑ Gheorghiade M, Gattis W, O'Connor C; et al. (2004). "Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial". JAMA. 291 (16): 1963–71. doi:10.1001/jama.291.16.1963. PMID 15113814.
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- 2Fix
- Diuretics
- Hormonal agents
- Organochlorides
- Alcohols
- Benzazepines
- Amides
- Benzanilides
- Systemic hormonal preparation stubs
- Antihypertensive agent stubs
